Autres langues Bristol-Myers Squibb Company

Actions

BMY

US1101221083

Marché Fermé - Nyse Autres places de cotation 22:00:02 01/05/2024			Varia. 5j.	Varia. 1 janv.
44,21 ^USD	+0,61%		-9,76%	-13,84%

01/05	BRISTOL-MYERS SQUIBB COMPANY : HSBC n'est plus positif	ZM
01/05	Malgré un fort recul lié aux soins anti-Covid, Pfizer relève ses prévisions	AW

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration	01/05
Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla...	30/04
A flurry of corporate results ahead of the Fed's rate decision	30/04
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK : Tesla, Snap, Alphabet, Microsoft, Anglo American...	30/04
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American...	30/04
Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb	30/04
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	30/04
Borsa di Italia: Dopo Microsoft, Alphabet, Tesla e Apple, Amazon deve fare il suo lavoro	30/04
IN DIRETTA DAI MERCATI: Tenaris, Generali, Caixabank, Eni, Leonardo, Stellantis, HSBC, Webuild, Samsung, Coca-Cola, Tesla, Caterpillar...	30/04
EN DIRECTO DESDE LOS MERCADOS: BBVA, Santander, Caixabank, Soltec, Ercros, Grifols, HSBC, Samsung, Coca-Cola, Tesla, Caterpillar...	30/04
Bolsa de Madrid: Tras Microsoft, Alphabet, Tesla y Apple, Amazon debe hacer su trabajo	30/04
J&J, Bristol Myers lose challenges to US drug price negotiation program	29/04
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases	29/04
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases	29/04
S&P 500 Q1 earnings estimated growth improves; stocks up for week	26/04
Bristol-Myers Squibb Says European Regulator Recommends Approval of Bladder Cancer Combination Therapy	26/04
Bristol Myers : avis favorable du CMHP pour Opdivo	26/04
Bristol Myers Gets CHMP Backing for Opdivo Combo in Bladder Cancer	26/04
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma	26/04
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma	26/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Christopher Boerner, PDG de Bristol-Myers : Un pipeline de 16 traitements, focus sur les neurosciences et l'oncologie

Le 09 janvier 2024 à 19:06